130 related articles for article (PubMed ID: 14686977)
1. The treatment of cutaneous T-cell lymphoma with photopheresis.
Zic JA
Dermatol Ther; 2003; 16(4):337-46. PubMed ID: 14686977
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
Girardi M; Carlson K; Huang X; Corman SL; Edmundson P; Schmier J; Kale HP; Raina R; Foss F
J Dermatolog Treat; 2024 Dec; 35(1):2360568. PubMed ID: 38852942
[TBL] [Abstract][Full Text] [Related]
4. Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T-cell lymphoma.
Aires D; Abhyankar S
Hematol Oncol; 2023 Dec; 41(5):809-816. PubMed ID: 37974524
[TBL] [Abstract][Full Text] [Related]
5. Mode of action, indications and recommendations on extracorporeal photopheresis (ECP).
Cho A; Paulitschke V; Knobler R
J Dtsch Dermatol Ges; 2023 Nov; 21(11):1369-1380. PubMed ID: 37723908
[TBL] [Abstract][Full Text] [Related]
6. Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma.
Tsai YC; Schlaepfer T; Ignatova D; Chang YT; Valaperti A; Amarov B; Blanchard G; Pehr K; Vonow-Eisenring M; Urosevic-Maiwald M; Hoetzenecker W; Pascolo S; Iselin C; Fassnacht C; Dimitriou F; Bobrowicz M; Guenova E
Br J Dermatol; 2023 Oct; 189(5):603-611. PubMed ID: 37409661
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal Photopheresis in Dermatological Diseases.
Terhaar H; Saleem M; Yusuf N
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474257
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal Photopheresis-An Overview.
Cho A; Jantschitsch C; Knobler R
Front Med (Lausanne); 2018; 5():236. PubMed ID: 30211164
[TBL] [Abstract][Full Text] [Related]
9. Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
Ion A; Popa IM; Papagheorghe LM; Lisievici C; Lupu M; Voiculescu V; Caruntu C; Boda D
Dis Markers; 2016; 2016():9602472. PubMed ID: 27821903
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma.
Ninosu N; Melchers S; Kappenstein M; Booken N; Hansen I; Blanchard M; Guenova E; Assaf C; Goerdt S; Nicolay JP
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201568
[TBL] [Abstract][Full Text] [Related]
11. Management of cutaneous T-cell lymphoma.
Duhovic C; Child F; Wain EM
Clin Med (Lond); 2012 Apr; 12(2):160-4. PubMed ID: 22586794
[No Abstract] [Full Text] [Related]
12. Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome.
Breen ID; Brumfiel CM; Patel MH; Rosenthal AC; Rule WG; DiCaudo DJ; Craig FE; Pittelkow MR; Mangold AR
JAAD Case Rep; 2021 Mar; 9():24-27. PubMed ID: 33604439
[No Abstract] [Full Text] [Related]
13. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
Br J Dermatol; 2023 Oct; 189(5):e97. PubMed ID: 37879744
[No Abstract] [Full Text] [Related]
14. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies.
Campbell BA; Dobos G; Haider Z; Prince HM; Bagot M; Evison F; van der Weyden C; McCormack C; Ram-Wolff C; Miladi M; Scarisbrick JJ
Blood Adv; 2023 Nov; 7(21):6639-6647. PubMed ID: 37648672
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Cellular Resistance Process in Treated Cells Via Extracorporeal Photopheresis.
Arjmand B; Rezaei Tavirani M; Jahani Sherafat S; Rezaei M; Farahani M; Rezaei Tavirani M
J Lasers Med Sci; 2023; 14():e46. PubMed ID: 38028865
[No Abstract] [Full Text] [Related]
16. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status.
Zic JA
Curr Opin Oncol; 2012 Jan; 24 Suppl 1():S1-10. PubMed ID: 22157241
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
